| REVIEW |
|
| Year : 2015 | Volume
: 8
| Issue : 1 | Page : 69-81 |
|
|
Camptothecin and taxol – from nature to bench to bedside
Mansukh C Wani
RTI International, Center for Drug Discovery, Research Triangle Park, NC, USA
Correspondence Address:
Mansukh C Wani
RTI International, Center for Drug Discovery, 3040 Cornwallis Road, PO Box 12914, Research Triangle Park, NC 27709-2194
USA
 Source of Support: None, Conflict of Interest: None  | 2 |
DOI: 10.7707/hmj.355
|
|
|
Camptothecin (CPT) and taxol are secondary metabolites found, respectively, in the wood bark of Camptotheca acuminata, a native of China, and Taxus brevifolia, found in the Pacific north-west coastal region of the USA. The compounds were isolated by the bioassay-guided fractionation of the crude plant material and their structures established by single crystal X-ray analysis. Both compounds have unique mechanisms of antitumour activity. Camptothecin inhibits an enzyme, topoisomerase I, involved in DNA replication. Taxol binds to a protein, tubulin, thus inhibiting cell division. Currently, two analogues of camptothecin, topotecan (Hycamtin®, GlaxoSmithKline, Brentford, UK) and irinotecan (Campto®, Pfizer Ltd, New York, NY, USA), and taxol and its analogues, docetaxel (Taxotere®, Sanofi-Aventis Ltd, Guilford, UK) and cabazitaxel (Jevtana®, Sanofi-Aventis Ltd, Guilford, UK), are approved for clinical use in the USA by the Food and Drug Administration (FDA). The camptothecin analogues are used to treat ovarian, colorectal and small-cell lung cancers. Taxol is used extensively to treat refractory ovarian, breast and non-small-cell lung cancers and Kaposi's sarcoma. Docetaxel has been a very important drug for the treatment of breast cancer and cabazitaxel is FDA approved for the treatment of hormone-refractory prostate cancer.
|
|
|
|
| [PDF]* |
|
 |
|
